An experimental dementia drug slowed clinical decline in people with early-stage Alzheimer’s disease in a phase 3 clinical trial. The findings led to accelerated FDA approval of the medication.
- December 19, 2022
We talk a lot about the role that physician-scientists play as “interpreters” and “translators” between the worlds of medicine and research. But that often means stepping outside of one’s narrow area of scientific expertise to help colleagues and trainees understand clinically relevant data that informs patient care, even if it’s far from what you look at in your own research.
- December 19, 2022
Researchers from the Yale School of Medicine Section of Cardiovascular Medicine outline emerging areas of research in cardiovascular medicine. Explore the latest advances in scholarly and scientific publishing.
- December 13, 2022
While the number of patients they studied is too small for their results to be definitive, Yale researchers—using their extensive experience with two existing medications—have published initial evidence that those drugs, given together, can mitigate or even eliminate brain fog.
- November 30, 2022Source: NPR
Christopher Van Dyck, MD, professor of psychiatry and director of the Alzheimer's Disease Research Unit, spoke about an experimental drug for Alzheimer's disease patients at the Clinical Trials on Alzheimer's Disease meeting in San Francisco in November.
- November 30, 2022Source: YaleNews
Yale researchers have found that the disease’s debilitating symptoms may be the result of swelling caused by amyloid plaques in the brain.
- November 09, 2022Source: YaleNews
Using an innovative technology that enables imaging of two individuals during live and natural conditions, Yale researchers have identified specific brain areas in the dorsal parietal region of the brain associated with the social symptomatology of autism.
- November 01, 2022Source: The Washington Post
Joel Gelernter, MD, Foundations Fund Professor of Psychiatry and Professor of Genetics and of Neuroscience, spoke to The Washington Post about the Million Veteran Program (MVP), a federally funded genetic biobank and the single-largest source of genetic data on Black Americans.
- October 21, 2022
The Kavli Institute for Neuroscience is now accepting applications for the 2023 Kavli Postdoctoral Award for Academic Diversity.
- October 19, 2022
A new Yale study of neuron activity in the brain has revised scientists’ understanding of how the brain processes and responds to rewards. Marina Picciotto, PhD, Charles B. G. Murphy Professor of Psychiatry and Professor in the Child Study Center, of Neuroscience and of Pharmacology, is the study’s senior author.